STAT Plus: Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial
DAMIAN DOVARGANES/AP
The company secured accelerated approval for the drug, called Trodelvy, to treat women with triple-negative breast cancer.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario